Air pollution and alveolar health
- PMID: 40903050
- PMCID: PMC12406027
- DOI: 10.1183/16000617.0280-2024
Air pollution and alveolar health
Abstract
Exposure to air pollution has been associated with up to 9 million premature deaths per year worldwide, with the respiratory system a key site for its effects. Air pollution exposure is a well-established risk factor for the development and exacerbation of airways diseases and lung cancer, however relatively little is known regarding the risks associated with air pollution interacting with areas of gas exchange - the alveoli and pulmonary interstitium. In recent years, evidence has emerged identifying a role in the development and progression of sub-clinical interstitial lung abnormalities as well as progression and risk of exacerbation of fibrotic interstitial lung diseases. This review outlines the epidemiologic evidence that air pollution perturbs alveolar health. It considers the different components of ambient air pollution, how penetration to the alveoli is determined by particle size and whether the response to alveolar exposure may be modulated by personal susceptibility factors. We discuss potential acute and chronic pathogenic mechanisms of injury upon the pulmonary interstitium and how these may contribute to the development and/or progression of interstitial processes. Finally, we explore current knowledge gaps and the potential for air pollution interventions in vulnerable individuals to support alveolar homeostasis and so prevent disease development and/or progression.
Copyright ©The authors 2025.
Conflict of interest statement
Conflict of interest: C. Sofia has nothing to disclose. J.G.H. Parkin reports grants from Wessex Medical Research and is a named post-doctoral researcher on M. Loxham's BBSRC David Phillips Fellowship. J.A. Bell reports support for the present study from NIHR Southampton Biomedical Research Centre, grants from AAIR charity and NIHR Southampton Biomedical Research Centre, and support for attending meetings from the European Respiratory Society. L.S.N. Dean reports support for the present study from AXA Research fund. L.J. Edgeway, L. Sayer and N.H.C. Easton have nothing to disclose. D.E. Davies reports grants from Boehringer Ingelheim, consultancy fees from Synairgen, a leadership role with Asthma Allergy and Inflammation Research Charity, and stock (or stock options) with Synairgen. B.G. Marshall has nothing to disclose. S.T. Holgate reports grants from UKRI Clean Air Champion, University Grant and NERC Council Member, consultancy fees from Dyson, Healthy Air Technologies Ltd, participation on a data safety monitoring board or advisory board with Dyson, Healthy Air Technologies Ltd, a leadership role with RCP Special Advisor on Air Quality, DEFRA Advisor on Air Quality Information Systems (AQIS), NE Board Director, Synairgen, and stock (or stock options) with Synairgen, and the following financial (or non-financial) interests: Synairgen. L. Richeldi reports grants from Boehringer Ingelheim and Italian Drug Agency, consultancy fees from Biogen, Celgene, Boehringer Ingelheim, Bristol Myers Squibb, Pliant Therapeutics, BMS, CSL Behring, FibroGen, Veracyte and Chiesi, payment or honoraria for lectures, presentations, manuscript writing or educational events from Boehringer Ingelheim, Zambon and Chiesi, support for attending meetings from Boehringer Ingelheim and Roche, and participation on a data safety monitoring board or advisory board with Roche, Boehringer Ingelheim, FibroGen and Promedior. M.G. Jones reports grants from the Medical Research Council, Asthma+Lung UK, Royal Society, AAIR Charity and Boehringher Ingelheim, and consultancy fees from Skyhawk Therapeutics. M. Loxham reports support for the present study from BBSRC David Phillips Fellowship (BB/V004573/1), grants from BBSRC Future Leader Fellowship (BB/P011365/1), Academy of Medical Sciences Springboard award, MRC Studentship (code 2746858), Asthma, Allergy, and Inflammation Research (AAIR) Charity UK, Wessex Medical Research and Gerald Kerkut Charitable Trust, support for attending meetings from British Thoracic Society, and is a Member of the UK expert Committee on the Medical Effects of Air Pollution.
Figures


References
-
- Schraufnagel DE, Balmes JR, Cowl CT, et al. Air pollution and noncommunicable diseases: a review by the forum of international respiratory societies’ environmental committee, part 1: the damaging effects of air pollution. Chest 2019; 155: 409–416. doi: 10.1016/j.chest.2018.10.042 - DOI - PMC - PubMed
-
- World Health Organization . Ambient (outdoor) air pollution. Date last updated: 24 October 2024. Date last accessed: 22 July 2025. www.who.int/news-room/fact-sheets/detail/ambient-(outdoor)-air-quality-a...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical